Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOZART: Monalizumab and Durvalumab in Small Cell Lung Cancer
NCT05903092Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab in small cell lung cancer (SCLC). Started Sep 2023; status: recruiting.
02
Drugs
monalizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05903092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903092.